SAN DIEGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today
announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of
$15.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares
of common stock. The shares began trading on The NASDAQ Global Select Market on January 26, 2017 under the symbol “ANAB.”
Credit Suisse and Stifel acted as joint book-running managers for the offering. JMP Securities and Wedbush
PacGrow acted as co-managers.
A registration statement relating to these securities was filed with the Securities and Exchange Commission and
declared effective on January 25, 2017. The offering was made only by means of a prospectus. Copies of the final prospectus
for the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue,
New York, NY 10010, or by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com; or Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720,
or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact: Monique Allaire THRUST Investor Relations 617.895.9511 monique@thrustir.com
